CLINICAL_TRIALS
trial_result
· 2012-05-30
Clinical Trial Update: Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial [Phase 3]
Summary
Phase 3 COMFORT-II trial evaluating a JAK inhibitor for myelofibrosis has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis | Phase 3 | Status: COMPLETED | Results posted: 2012-05-30